ABOUT US & SUPPORT
RESOURCES
PRODUCTS
SECTOR PUBLICATIONS
TOPICS
CURRENT ISSUE
|
BIOLASE Files Patent Infringement Lawsuit Against European Competitor
Posted on April 25, 2012 at 09:00 AM EDT
IRVINE, CA -- (Marketwire) -- 04/25/12 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that it had filed a lawsuit in the Dusseldorf Patent Litigation Court asserting that one of its European competitors is infringing on BIOLASE European Patent EP 1 560 470, which relates to the output of optical energy of lasers. The lawsuit, filed on April 13, 2012, seeks both cash damages and injunctive relief from the courts. The lawsuit was filed after failed attempts were made to create an amicable business arrangement between the two companies. Federico Pignatelli, Chairman and CEO, said, "BIOLASE is committed to asserting its rights in its extensive patent portfolio in the U.S. and internationally. With more than 280 U.S. and international patents and patents pending, the Company has invested heavily in its intellectual property portfolio for laser dentistry and other medical fields. We will not tolerate what we believe to be infringement of our patents, and we will be very aggressive in protecting our rights." About BIOLASE Technology, Inc. For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, and YouTube at http://www.youtube.com/user/Rossca08. This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by BIOLASE management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and BIOLASE undertakes no obligation to update such statements. For further information, please contact: Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Markets are closed on certain holidays. Stock Market Holiday List By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. Press Release Service provided by PRConnect. Stock quotes supplied by Telekurs USA Postage Rates Bots go here |
Home | Resources | Products | Cell Biology | Cytometry & Cell Sorting | Dermatology & Cosmetic Surgery | DNA Sequencing & Analysis
Microscopy | Molecular Imaging | OCT | Oncology & Cancer | Ophthalmology | Specialties | Spectroscopy
Current Issue | Archives | Privacy Policy | Terms & Conditions | Contact Us | About Us | Site Map | RSS | Webmaster
OptoIQ | Industrial Laser Solutions | Strategies Unimited | PennWell Websites | PennWell Events
Copyright © 2011: PennWell Corporation
